Literature DB >> 20306022

Effects of GH-IGF-I excess and gonadal status on bone mineral density and body composition in patients with acromegaly.

M Madeira1, L V Neto, G A B de Lima, R O Moreira, L M C de Mendonça, M R Gadelha, M L F Farias.   

Abstract

SUMMARY: Studies on body composition and bone mineral density in acromegaly have conflicting results. Our data point to an increase in lean mass, a decrease in adipose tissue, and that the anabolic effect of GH on bone is partially dependent on modifications in body composition.
INTRODUCTION: The effects of growth hormone (GH) and insulin-like growth factor I (IGF-I) excess and gonadal status on bone mineral density (BMD) and body composition (BC) in acromegalic patients are uncertain.
METHODS: Bone mineral density and BC were evaluated by dual-energy X-ray absorptiometry (Prodigy-GE) in 75 patients (22 men and 53 women) with acromegaly, mean age 48.9 ± 14.5 years. Acromegaly was considered "controlled" when serum IGF-I was within the specific age-adjusted reference range, and serum GH was lower than 2.5 ng/mL. Comparisons between groups were performed using unpaired t test or Mann-Whitney U test. Categorical variables were analyzed by chi-square (x (2)) test. In order to compare data of different subgroups stratified by disease activity and gonadal status, one-way analysis of variance (ANOVA) and Bonferroni post hoc analysis were performed. To evaluate the correlation between GH and IGF-I and densitometric parameters, Pearson and Spearman rank order correlation were performed, as appropriate.
RESULTS: There were no differences in BMD when considering disease activity and gonadal status. Active disease and eugonadism were positively correlated to an increase in lean mass and a decrease in fat mass. After multiple linear regression, there were positive correlations between GH and Z-score at lumbar spine and between lean mass and BMD at proximal femur.
CONCLUSION: Our data support that GH-IGF-I excess and eugonadism have great influence on BC modifications and that the anabolic effects of GH-IGF-I on bone are, at least in part, dependent on these alterations in body composition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20306022     DOI: 10.1007/s00198-009-1165-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  28 in total

1.  Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine.

Authors:  M J Kayath; J G Vieira
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

2.  Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function.

Authors:  Marek Bolanowski; Jacek Daroszewski; Marek Medraś; Beata Zadrozna-Sliwka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

3.  Characteristics of the human lymphocyte insulin receptor.

Authors:  J R Gavin; P Gorden; J Roth; J A Archer; D N Buell
Journal:  J Biol Chem       Date:  1973-03-25       Impact factor: 5.157

4.  Effect of growth hormone on osteoblasts and demonstration of somatomedin-C/IGF I in bone organ culture.

Authors:  H Stracke; A Schulz; D Moeller; S Rossol; H Schatz
Journal:  Acta Endocrinol (Copenh)       Date:  1984-09

5.  Decreased trabecular bone biomechanical competence, apparent density, IGF-II and IGFBP-5 content in acromegaly.

Authors:  T Ueland; E N Ebbesen; J S Thomsen; L Mosekilde; K Brixen; A Flyvbjerg; J Bollerslev
Journal:  Eur J Clin Invest       Date:  2002-02       Impact factor: 4.686

6.  In acromegaly, increased bone mineral density (BMD) is determined by GH-excess, gonadal function and gender.

Authors:  Wojciech Zgliczynski; Magdalena Kochman; Waldemar Misiorowski; Piotr Zdunowski
Journal:  Neuro Endocrinol Lett       Date:  2007-10       Impact factor: 0.765

7.  Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status.

Authors:  Alfredo Scillitani; Claudia Battista; Iacopo Chiodini; Vincenzo Carnevale; Saverio Fusilli; Enrica Ciccarelli; Massimo Terzolo; Giuseppe Oppizzi; Maura Arosio; Maurizio Gasperi; Giorgio Arnaldi; Annamaria Colao; Roberto Baldelli; Maria Rosaria Ghiggi; Daniela Gaia; Carolina Di Somma; Vincenzo Trischitta; Antonio Liuzzi
Journal:  Clin Endocrinol (Oxf)       Date:  2003-06       Impact factor: 3.478

8.  Bone mineral density and circulating cytokines in patients with acromegaly.

Authors:  S Longobardi; C Di Somma; F Di Rella; N Angelillo; D Ferone; A Colao; B Merola; G Lombardi
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

9.  Insulin-like growth factor I (IGF-I) affects plasma lipid profile and inhibits the lipolytic action of growth hormone (GH) in isolated adipocytes.

Authors:  M Pascual; J Larralde; J A Martínez
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

10.  Biochemical assessment of bone formation and resorption in acromegaly.

Authors:  S Ezzat; S Melmed; D Endres; D R Eyre; F R Singer
Journal:  J Clin Endocrinol Metab       Date:  1993-06       Impact factor: 5.958

View more
  11 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.

Authors:  Tirissa J Reid; Zhezhen Jin; Wei Shen; Carlos M Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Jane Kostadinov; Kalmon D Post; Pamela U Freda
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

3.  Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment.

Authors:  Carlos M Reyes-Vidal; Hamed Mojahed; Wei Shen; Zhezhen Jin; Fernando Arias-Mendoza; Jean Carlos Fernandez; Dympna Gallagher; Jeffrey N Bruce; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2015-06-02       Impact factor: 5.958

4.  Exon 3-deleted growth hormone receptor isoform is not related to worse bone mineral density or microarchitecture or to increased fracture risk in acromegaly.

Authors:  J Pontes; M Madeira; C H A Lima; L L Ogino; F de Paula Paranhos Neto; L M C de Mendonça; M L F Farias; L Kasuki; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2019-08-07       Impact factor: 4.256

Review 5.  Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis.

Authors:  Cláudia Ribeiro de Moura; Sara Campos Lopes; Ana Margarida Monteiro
Journal:  Pituitary       Date:  2022-07-22       Impact factor: 3.599

6.  Functional evaluation of the joints in acromegalic patients and associated factors.

Authors:  Leandro Lemgruber Kropf; Miguel Madeira; Leonardo Vieira Neto; Mônica Roberto Gadelha; Maria Lucia Fleiuss de Farias
Journal:  Clin Rheumatol       Date:  2013-03-13       Impact factor: 2.980

7.  On the functional capacity and quality of life of patients with acromegaly: are they candidates for rehabilitation programs?

Authors:  Débora Pedroza Guedes da Silva; Fernando Silva Guimarães; Cristina Márcia Dias; Simone de Araujo Guimarães; Leandro Kasuki; Mônica Roberto Gadelha; Gustavo Bittencourt Camilo; Agnaldo José Lopes
Journal:  J Phys Ther Sci       Date:  2013-12-11

8.  What is the effect of peripheral muscle fatigue, pulmonary function, and body composition on functional exercise capacity in acromegalic patients?

Authors:  Agnaldo José Lopes; Débora Pedroza Guedes da Silva; Arthur de Sá Ferreira; Leandro Kasuki; Mônica Roberto Gadelha; Fernando Silva Guimarães
Journal:  J Phys Ther Sci       Date:  2015-03-31

9.  Osteoarticular changes in acromegaly.

Authors:  Zdenko Killinger; Martin Kužma; Lenka Sterančáková; Juraj Payer
Journal:  Int J Endocrinol       Date:  2012-09-12       Impact factor: 3.257

10.  IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction.

Authors:  Sjoerd D Joustra; Ferdinand Roelfsema; A S Paul van Trotsenburg; Harald J Schneider; Robert P Kosilek; Herman M Kroon; John G Logan; Natalie C Butterfield; Xiang Zhou; Chirine Toufaily; Beata Bak; Marc-Olivier Turgeon; Emilie Brûlé; Frederik J Steyn; Mark Gurnell; Olympia Koulouri; Paul Le Tissier; Pierre Fontanaud; J H Duncan Bassett; Graham R Williams; Wilma Oostdijk; Jan M Wit; Alberto M Pereira; Nienke R Biermasz; Daniel J Bernard; Nadia Schoenmakers
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.